Michael Morrissey Exelixis, Inc. (EXEL) insider trading activity

Michael Morrissey is President and CEO of EXELIXIS, INC.. Currently has a direct ownership of 916,742 shares of EXEL, which is worth approximately $32.6 Million. The most recent transaction as insider was on Nov 15, 2024, when has been sold 47,642 shares (Common Stock) at a price of $35.05 per share, resulting in proceeds of $1,669,852. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 917K

4.94% 3M change

50.29% 12M change

Total Value Held $32.6 Million

MICHAEL MORRISSEY Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 15 2024	SELL Payment of exercise price or tax liability	$1,669,852 $35.05 p/Share	47,642 Reduced 4.94%	916,742 Common Stock
Oct 03 2024	SELL Bona fide gift	-	16,298 Reduced 1.66%	964,384 Common Stock
Oct 01 2024	SELL Payment of exercise price or tax liability	$12,195,362 $26.3 p/Share	463,702 Reduced 32.1%	980,682 Common Stock
Oct 01 2024	BUY Exercise of conversion of derivative security	$11,716,800 $24.41 p/Share	480,000 Added 24.94%	1,444,384 Common Stock
May 15 2024	SELL Payment of exercise price or tax liability	$1,552,063 $20.99 p/Share	73,943 Reduced 7.12%	964,384 Common Stock
Feb 23 2024	BUY Grant, award, or other acquisition	-	241,670 Added 18.88%	1,038,327 Common Stock
Jan 11 2024	SELL Payment of exercise price or tax liability	$1,456,570 $22.86 p/Share	63,717 Reduced 7.41%	796,657 Common Stock
Jan 11 2024	BUY Grant, award, or other acquisition	-	250,374 Added 22.54%	860,374 Common Stock
Nov 07 2023	SELL Bona fide gift	-	116,893 Reduced 16.08%	610,000 Common Stock
Sep 06 2023	SELL Payment of exercise price or tax liability	$1,037,960 $22.27 p/Share	46,608 Reduced 6.03%	726,893 Common Stock
Sep 06 2023	BUY Grant, award, or other acquisition	-	188,005 Added 19.55%	773,501 Common Stock
Aug 31 2023	SELL Bona fide gift	-	56,221 Reduced 8.76%	585,496 Common Stock
Aug 28 2023	SELL Payment of exercise price or tax liability	$6,737,818 $22.18 p/Share	303,779 Reduced 32.13%	641,717 Common Stock
Aug 28 2023	BUY Exercise of conversion of derivative security	$5,511,600 $15.31 p/Share	360,000 Added 27.58%	945,496 Common Stock
Aug 15 2023	SELL Payment of exercise price or tax liability	$501,269 $21.51 p/Share	23,304 Reduced 3.83%	585,496 Common Stock
May 15 2023	SELL Payment of exercise price or tax liability	$642,875 $19.18 p/Share	33,518 Reduced 5.22%	608,800 Common Stock
Apr 03 2023	BUY Grant, award, or other acquisition	-	313,185 Added 32.78%	642,318 Common Stock
Feb 15 2023	SELL Payment of exercise price or tax liability	$208,317 $18.08 p/Share	11,522 Reduced 3.38%	329,133 Common Stock
Jan 30 2023	SELL Bona fide gift	-	37,994 Reduced 10.03%	340,655 Common Stock
Jan 24 2023	SELL Payment of exercise price or tax liability	$1,076,424 $17.36 p/Share	62,006 Reduced 14.07%	378,649 Common Stock
Jan 24 2023	BUY Exercise of conversion of derivative security	$420,000 $4.2 p/Share	100,000 Added 18.5%	440,655 Common Stock
Dec 07 2022	SELL Bona fide gift	-	106,010 Reduced 23.73%	340,655 Common Stock
Nov 15 2022	SELL Payment of exercise price or tax liability	$389,409 $16.71 p/Share	23,304 Reduced 4.96%	446,665 Common Stock
Aug 03 2022	SELL Payment of exercise price or tax liability	$500,803 $21.49 p/Share	23,304 Reduced 4.72%	469,969 Common Stock
Aug 03 2022	BUY Grant, award, or other acquisition	-	94,002 Added 16.01%	493,273 Common Stock

Also insider at

VERA

Vera Therapeutics, Inc. Healthcare